Position in AXSM
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$4,628,781
New position
Shares Held
27,386
first reported quarter
Ownership
0.053%
of shares outstanding
% of Portfolio
0.44%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Emerald Investment Advisers, LLC holds $26,447,335 across 6 Biotechnology names. AXSM ranks #2 (17.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
44,226 | $8,829,720 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
This page
|
27,386 | $4,628,781 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,388 | $4,162,984 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
8,012 | $3,577,678 | |
| 5 | TARS |
Tarsus Pharmaceuticals, Inc.
|
39,896 | $2,798,704 | |
| 6 | ACAD |
Acadia Pharmaceuticals Inc
|
110,039 | $2,449,468 |
All Filings in AXSM
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,628,781 | 27,386 | Shares | Sole | 2026-05-11 | |
| No filing history on record for this holder in this stock. | ||||||